Global oral care market
$58.2B
↑ 5.1% CAGR to 2036
Fastest growing segment
Whitening
↑ 8.1% yr — PAP leading premiumisation
Category challenger
nHAp
↑ Hydroxyapatite building RCT evidence
Regulatory watch
Charcoal
↓ ADA/BDA negative evidence active
Top five signals this month Ranked by consultant relevance
01
Clinical / restorative
A new RCT gives early peri-implantitis a real nonsurgical evidence base

A randomized, assessor-blinded trial (Scientific Reports, May 2026; 80 implants, 26 patients, five arms over six months) found standard mechanical debridement, with or without chlorhexidine, ozone, or glycine air abrasion, significantly improved pocket depth, bleeding on probing, and plaque index in early peri-implantitis. No adjunct showed a statistically meaningful edge over plain mechanical care.

So what: Clients advising on implant maintenance protocols can now point to RCT-level support for standard nonsurgical care. There is no evidence base yet for upselling a premium adjunct therapy over basic mechanical debridement.

Consumer search and social signals also inform velocity rating.

Velocity
02
Therapeutic / preventive Regulatory
Hydroxyapatite splits into two separate stories: professional and consumer

CDT code D2991, in effect since 2024, lets dentists bill for chairside hydroxyapatite-regeneration scaffold treatment (Curodont Repair, CrystLCare) on incipient lesions. Separately, as of an April 2026 review, FDA still regulates toothpaste as a cosmetic product and has not approved hydroxyapatite toothpaste for anti-caries claims; that status is unchanged from the prior edition.

So what: These are now two distinct client conversations. A dental-practice client has a reimbursable chairside treatment to adopt; a consumer toothpaste brand still cannot make a US anti-caries claim and should keep marketing language at the cosmetic or "supports remineralization" level.

Consumer search and social signals also inform velocity rating.

Velocity
03
Periodontal
New BLIS oral-probiotic research is thin and mostly not about gum or caries outcomes

BLIS, the maker of the K12 and M18 probiotic strains, published a June 2026 summary of four new studies. Only one was a human clinical trial, and it measured chemotherapy-related oral mucositis in cancer patients, not caries or gum disease. The other three were in vitro or animal studies; one found BLIS M18 modestly raised biofilm pH in a lab caries model, with no clinical confirmation yet.

So what: This round of evidence does not support upgrading BLIS K12/M18's evidence tier for the caries or periodontal claims the category is usually marketed on. Treat it as company-sponsored and exploratory until independent, disease-relevant human trials appear.

Consumer search and social signals also inform velocity rating.

Velocity
04
Cosmetic / whitening
Charcoal toothpaste's ADA problem has not moved

Consumer media coverage questioning charcoal toothpaste continues to circulate widely, but it traces back to the ADA's standing position (insufficient evidence of safety and efficacy, enamel-abrasion concern) rather than any new 2025 or 2026 ADA statement or Seal of Acceptance decision.

So what: Nothing has changed for clients weighing whether to enter or exit this category. The amber alert stands as written.

Consumer search and social signals also inform velocity rating.

Velocity
05
Market / commercial
The oral care market keeps its steady, toothpaste-anchored growth path

The global oral care market is sized at roughly USD 58.2 billion in 2026, projected to reach USD 95.7 billion by 2036 at a 5.1% CAGR. Toothpaste remains the anchor category at roughly 70% share; whitening, sensitivity, and herbal formats are cited as the premium-mix drivers.

So what: Growth here is steady and toothpaste-led, not driven by any single breakout ingredient this cycle. Client positioning in whitening and sensitivity sub-segments remains the more defensible growth story than betting on an emerging ingredient alone.

Consumer search and social signals also inform velocity rating.

Velocity
Topics to watch
Oral probiotics / synbiotics
Evidence is directionally positive but inconsistent across meta-analyses. BLIS's June 2026 research summary does not move caries or gum claims. Substantiation remains the gating issue.
Peri-implantitis management
A May 2026 five-arm RCT supports standard mechanical debridement for early peri-implantitis, with no adjunct clearly ahead. The opening is in maintenance protocols, not premium adjuncts.
Hydroxyapatite (nHAp)
Active US trials are building the evidence base for remineralization and dentin hypersensitivity claims, ahead of any change in FDA classification.
E-commerce and sustainability
E-commerce share and plant-based, biodegradable formulation growth are outpacing ingredient innovation as commercial levers in the category.
Regulatory radar
WatchCharcoal toothpaste: no ADA Seal recognition or safety consensus. No new ADA statement this cycle.
WatchHydroxyapatite toothpaste: FDA still treats toothpaste as cosmetic, so no US anti-caries claim. Reconfirmed as of April 2026.
MonitorCDT D2991: chairside hydroxyapatite regeneration is billable on incipient lesions, a separate story from consumer toothpaste.
MonitorPAP+ whitening: adoption broadening across DTC brands. No material new clinical evidence this cycle.